Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Public ClinicalTrials.gov record NCT02670577. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The scope of this study is to measure the impact of MammaPrint on treatment in Hormone Receptor (HR)-positive HER2-negative breast cancer patients. In addition, the impact of MammaPrint on treatment in patients with T1a/T1b and pN0/pN1 (up to 1 node), Triple Negative or HER2-positive tumors will be assessed.
Study identification
- NCT ID
- NCT02670577
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 481 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2015 (Type not available)
- Primary completion
- Apr 30, 2017 (Actual)
- Completion
- Aug 2017 (Actual)
- Last update posted
- Jun 27, 2018
2015 – 2017
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Desert Regional Medical Center | Palm Springs | California | 92262 | — |
| University of Miami | Miami | Florida | 33442 | — |
| St. Joseph's Women's Hospital | Tampa | Florida | 33607 | — |
| The Cancer Center at DeKalb Medical | Decatur | Georgia | 30033 | — |
| Cadence Cancer Center | Warrenville | Illinois | 60555 | — |
| Methodist Hospital | Merrillville | Indiana | 46410 | — |
| Community Healthcare System | Munster | Indiana | 46321 | — |
| Western Maryland Health System | Cumberland | Maryland | 21502 | — |
| Sparrow Cancer Center | Lansing | Michigan | 48911 | — |
| Essex Oncology | Belleville | New Jersey | 07109 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Akron General Medical Center | Akron | Ohio | 44302 | — |
| University of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| St. Mary Medical Center | Langhorne | Pennsylvania | 19047 | — |
| St. Clair Hospital | Pittsburgh | Pennsylvania | 15102 | — |
| Aurora Cancer Care | Milwaukee | Wisconsin | 53226 | — |
| Columbia St. Mary's | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02670577, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2018 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02670577 live on ClinicalTrials.gov.